Skip to content

Efficacy Testing of Chenopodium Formosanum Extracts on Skin Beauty

Efficacy Testing of Chenopodium Formosanum Extracts on Skin Beauty

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05591352
Enrollment
300
Registered
2022-10-24
Start date
2022-11-01
Completion date
2023-09-30
Last updated
2023-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Condition

Brief summary

To assess Chenopodium formosanum extracts on skin condition improvement

Interventions

DIETARY_SUPPLEMENTChenopodium formosanum extracts sachet

consume 1 sachet per day

DIETARY_SUPPLEMENTPlacebo sachet

consume 1 sachet per day

Sponsors

TCI Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Healthy adults aged above 20 years old

Exclusion criteria

* Subject who is not willing to participate in this study. * Patients with diseases of the skin, liver, kidney. * Subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder. * Female who is pregnant or nursing or planning to become pregnant during the course of the study. * Received facial laser therapy, chemical peeling or UV overexposure (\> 3 hr/week) in the past 4 weeks. * Constant drug use * Students who are currently taking courses taught by the principal investigator of this trial.

Design outcomes

Primary

MeasureTime frameDescription
The change of skin textureChange from Baseline skin texture at 8 weeksVISIA Complexion Analysis System was utilized to measure skin texture. Units: arbitrary units
The change of skin elasticityChange from Baseline skin elasticity at 8 weeksCutometer® MPA580 was utilized to measure skin elasticity. Units: arbitrary units
The change of skin collagen densityChange from Baseline skin collagen density at 8 weeksDermaLab® Series SkinLab Combo was utilized to measure skin pores. Units: arbitrary units
The change of skin wrinklesChange from Baseline skin wrinkles at 8 weeksVISIA Complexion Analysis System was utilized to measure skin wrinkles. Units: arbitrary units

Secondary

MeasureTime frameDescription
The change of skin moistureChange from Baseline skin moisture at 8 weeksCorneometer® CM825 was utilized to measure skin moisture. Units: arbitrary Corneometer® units 0-120
The change of skin poresChange from Baseline skin pores at 8 weeksVISIA Complexion Analysis System was utilized to measure skin pores. Units: arbitrary units
The change of AGEs of bloodChange from Baseline AGEs at 8 weeksFasting venous blood was sampled to measure concentrations of AGEs
The change of transepidermal water loss (TEWL)Change from Baseline TEWL at 8 weeksTewameter® TM 300 was utilized to measure TEWL. Units: g/hm²
The change of skin melanin indexChange from Baseline skin melanin index at 8 weeksMexameter® MX18 was utilized to measure skin melanin index. Units: arbitrary units
The change of skin L* valueChange from Baseline L* value at 8 weeksChroma Meter MM500 was utilized to measure skin L\* value. Units: arbitrary units, 0-100
The change of skin erythema indexChange from Baseline skin erythema index at 8 weeksMexameter® MX18 was utilized to measure skin erythema index. Units: arbitrary units

Other

MeasureTime frameDescription
The change of liver function biomarkers (AST, ALT) of bloodChange from Baseline liver function biomarkers at 8 weeksFasting venous blood was sampled to measure liver function biomarkers
The change of self-assessment skin conditionChange from Baseline skin condition at 8 weeksA self-assessment questionnaire was collected to evaluate skin condition
The change of renal function biomarkers (creatinine, BUN) of bloodChange from Baseline renal function biomarkers at 8 weeksFasting venous blood was sampled to measure renal function biomarkers

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026